Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Pfizer (PFE) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
May 5, 2026 6:46 AM EDTPfizer (NYSE: PFE) reported Q1 EPS of $0.75, $0.03 better than the analyst estimate of $0.72. Revenue for the quarter came in at $14.5 billion versus the consensus estimate of $13.84 billion.
GUIDANCE:
Pfizer sees FY2026 EPS of $2.80-$3.00, versus the consensus of $2.96.
For earnings history and earnings-related data on Pfizer (PFE) click here.
... More